Drug industry receives some long-awaited tax breaks in government’s latest budget.
|
Indian firm receives U.S. approval to market Simvastatin, a rival to Merck’s Zocor.
|
Drug maker signs deal with government for new drug discovery research.
|
Indian drug company receives funds to develop diabetes drug from German giant.
|
Generic drug makers get to keep 180-day exclusivity when the FDA de-lists patents.
|
Federal court denies a rehearing on Lipitor patent case.
|
Gilead Sciences licenses AIDS treatment Tenofovir to eight more Indian companies.
|
The pharma company launches the world’s first novel combination drug for asthma.
|
Indian pharmaceutical plans to relocate Irish manufacturing unit to Romania.
|
Indian drug maker will test California company’s anti-diarrhea treatment.
|
Drug firms forge alliances to create dermatological products for Europe.
|
Generics companies scramble as Merck’s cholesterol-lowering statin loses its patent.
|
The Indian pharmaceutical giant buys Romanian and Belgian generic drug companies.
|
Biocon wins bid to obtain Nobex’s assets, and Ranbaxy will acquire Glaxo’s Italian arm.
|
The country’s pharmaceutical firms grow up and out while multinationals move in, but the giants don’t always get what they want.
|
Indian pharma company outbids its rival Ranbaxy and others in a $570-million deal.
|
Cancer drug patent outcome elates Indian pharma industry as generics hike production.
|
Investors and analysts embrace Pfizer plan to shed consumer products.
|
Indian pharmaceutical giant starts joint venture to market anti-retroviral products in South Africa.
|
Less stringent regulations in Asian nations reduce the timeline for drug discovery.
|
Page
1
of
2
|